If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
139
results.
Updated on
01/09/2024 [07:08:00]
Results 25 to 50 of 139
Absstract of: WO2024168793A1
The present application discloses a safety insulin pen needle, comprising: a needle hub, wherein a fixing stud protruding along with an injection needle is arranged on the needle hub, and clamping steps are arranged on the surface of the fixing stud; a protective cap, wherein the injection needle is inserted into the protective cap, a spring is sandwiched between the protective cap and the needle hub so that the protective cap can axially move relative to the needle hub to expose or cover a needle tip of the injection needle, a flange is arranged on the outer wall of the protective cap, a first limiting step and a second limiting step are arranged on the inner wall of the protective cap in an insertion direction of the injection needle, and the inner diameter size of the second limiting step is smaller than that of the first limiting step; a needle cap, assembled and fixed to the needle hub and covering the protective cap, wherein a through hole allowing the protective cap to extend out is formed in the needle cap, and the through hole limits the flange; and a limiting block, located in an inner cavity of the protective cap and sleeved on the injection needle, wherein a clamping jaw fitted to the clamping steps is arranged at a first end of the limiting block, and a second end of the limiting block is fitted to the first limiting step or the second limiting step to stop the protective cap.
Absstract of: EP4417124A2
Apparatus and methods are operative to probe the condition of a sensor either initially, at any point thereafter or continuously during a continuous sensor operation for measuring an analyte in a bodily fluid (such as performed by, e.g., a continuous glucose monitoring (CGM) sensor). Results of the probe may include calibration indices determined from electrical signals obtained during the probe. The calibration indices may indicate whether in-situ adjustment of the sensor's calibration should be performed either initially and/or at random check points. Probing potential modulation parameters also may be used during analyte calculations to reduce the effects of lot-to-lot sensitivity variations, sensitivity drift during monitoring, temperature, interferents, and/or the like. Other aspects are disclosed.
Absstract of: CA3235006A1
The current subject matter is directed to an ecosystem that enables interconnection of a blood glucose monitor and a continuous glucose monitor for data exchange and processing of shared data. The communication of data and instructions enables user-facing functionality and feedback to a user. The connection between the blood glucose monitor and the continuous glucose monitor may also provide for improved functionality of either or both devices. For example, measurements may be used for calibration or verification processes. Data streams from other data sources may be correlated or integrated with the data obtained by the blood glucose monitor and/or the continuous glucose monitor. The correlation or the integration of other data streams may be used to provide additional alerts or functionality to the user. Aspects of the current subject matter are also directed to integration of blood glucose monitor and continuous glucose monitor functionalities in one device or structure.
Absstract of: WO2023064328A1
Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and/or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.
Absstract of: EP4418213A2
Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.
Absstract of: USRE50080E
Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc. Another technique provides adaptation of priming dose size at mealtimes for overall better glycemic control and also adapting to longer-term changes in a patient's needs. Adaptation calculations use a receding-horizon window of recent values of the adapted parameter. Doses of a counter-regulatory agent (e.g., glucagon) may also be delivered in response to information about estimated accumulation of exogenously infused insulin (subcutaneously, intramuscularly, intraperitoneally, or intravenously) and/or the effect insulin might have on glucose levels (blood glucose concentration or interstitial fluid glucose concentration).
Absstract of: US2024269383A1
Disclosed herein are apparatuses and methods incorporating an infusion pump and a CGM that can include software that automatically populates a blood glucose section of a bolus calculator with a most recent valid CGM value. The software can additionally be programmed to automatically populate the bolus calculator with a single CGM reading only when one or more predefined conditions are met that aid in mitigating the risk of inaccurate and/or invalid singleCGMreadings.
Absstract of: US2024268715A1
According to examples, an apparatus may include a processor and a memory on which is stored machine-readable instructions that when executed by the processor, cause the processor to access a detected polarization state of light reflected from an individual's eye, identify conditions associated with a detection of the polarization state of the light reflected from the individual's eye, determine whether the identified conditions match certain conditions within predefined difference levels, and determine a variance in the detected polarization state of the light from a previously detected polarization state based on a determination that the identified conditions match the certain conditions within the predefined difference levels, in which a change in a glucose level of the individual is to be determined based on the determined variance.
Absstract of: US2024268723A1
The present disclosure relates to a smart contact lens for diabetes diagnosis in which a diabetic diagnosis sensor is composed of platinum-plated electrodes, and a driving system using the same.The smart contact lens of the present disclosure is easy to mass-produce, has good wireless power transfer efficiency due to high electrical conductivity, may perform good communication with an external driving board, and may perform physically and electrochemically stable driving.
Absstract of: US2024268724A1
Disclosed herein is a system and method providing an improvement to a medical device such as a wearable CGM as part of an automated drug delivery system. The improvement provides optical energy to the wound site caused by the insertion of a sensing element into the skin of the user to hasten the healing of the wound, resulting in an improvement in the accuracy of readings for the CGM in a timelier manner. This tends to lessen the effect of the warm-up period of the CGM and improves the response of the automated drug delivery system to better manage the user's blood glucose levels.
Absstract of: US2024268768A1
A method for treating type 2 diabetes (T2D) is provided. The method comprises diagnosing a subject as suffering from T2D or as being pre-diabetic; monitoring the response to glucose stimulation of at least one islet in the pancreas of the subject by quantitatively imaging glucose metabolism in vivo; establishing a target range for the response to glucose stimulation of the at least one islet; and upregulating cathelicidin gene expression in the subject until the monitored response to glucose stimulation is within the target range.
Absstract of: WO2024167041A1
The present invention relates to a smart contact lens for diagnosing diabetes, comprising a diabetes diagnosis sensor which is a platinum plated electrode, and a driving system using same. The smart contact lens of the present invention is easy to mass-produce, has excellent wireless power transfer efficiency due to having high electrical conductivity, is capable of good communication with an external driving board, and is can be stably driven physically and electrochemically.
Absstract of: WO2024164860A1
Disclosed in the present application is a blood glucose measurement apparatus, comprising a body and an electrochemical sensor electrically connected to the body. The electrochemical sensor outputs an electrical signal on the basis of glucose in parotid gland saliva; and a signal processing circuit is provided in the body, and the signal processing circuit is connected to the electrochemical sensor by means of an electrode connector provided on the body, and is used for processing the electrical signal, so as to obtain and output a blood glucose value. The present measurement apparatus can obtain a blood glucose value of a user without needing a blood sample, such that the user does not need to puncture his/her skin to collect blood, thereby avoiding causing trauma to a patient.
Absstract of: WO2024167973A1
Disclosed herein are intravascular artificial pancreas devices and methods for their manufacture.
Absstract of: WO2024167882A2
A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and a multiple metal protective system including multiple metals incorporated in and/or in close proximity to a surface of the analyte indicator that reduce deterioration of the analyte indicator.
Absstract of: WO2024167483A1
Organometallic redox mediator compounds, such as substituted ferrocenes or other metallocenes, and redox polymers comprising the organometallic redox mediators are described. The organic groups of the organometallic redox mediators can be substituted with multiple (e.g., at least three or at least four) electron-donating substituents, which can reduce the redox potential of the redox mediator compared to the corresponding unsubstituted redox mediator. Electrodes coated with the redox polymers or blends comprising the redox polymers are described, as are related electrochemical sensors. In addition, methods of using the sensors to detect biological analytes of interest, such as glucose or ketones, are described.
Absstract of: GB2627164A
A glucose monitoring system comprising a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level of a subject, and a reader device. The reader device comprises a wireless communication circuitry configured to receive the data indicative of the analyte level and a glycated hemoglobin level for the subject, a non- transitory memory, and at least one processor communicatively coupled to the non- transitory memory and the analyte sensor and configured: calculate a plurality of personalized glucose metrics for the subject using at least one physiological parameter and at least one of the received data indicative of the analyte level or the received glycated hemoglobin level, and a display, on a display of the reader device, a report comprising a plurality of interfaces including at least two or more of the received data indicative of the analyte level, the received glycated hemoglobin level, or the calculated plurality of personalized glucose metrics, wherein the plurality of interfaces comprising the report are based on a user type.
Absstract of: WO2023057561A1
The present disclosure provides for a novel method of predicting life expectancy in persons, in particular in persons that have an a priori reduced life expectancy, for instance if they suffer from ischemic heart disease (IHD), IHD-related depression, ANSD, type 2 diabetes mellitus. Also disclosed is a related method for increasing life expectancy in human subjects, in particular in human subjects having an a priori reduced life expectancy. The disclosure also provides a method for evaluating the efficacy of drugs other treatment of ANSD. The present invention also provides a novel method for diagnosing and treating/preventing type 2 diabetes mellitus or IHD-related depression. Finally, the disclosure also provides a method for diagnosing autonomic homeostatic glucose dysregulation, and a novel method to re-establish normal homeostatic function, if disrupted, dysregulated or insufficient
Absstract of: EP4404212A2
Continuous glucose monitoring (CGM) data and insulin delivery data are used to generate more reliable projected alarms related to a projected glucose levels. A memory stores endogenous data related to measurements of glucose level in a patient, and also stores exogenous data, such as insulin on board, both of which are used by a processor to create projected alarms. Profiles of CGM data are created for use in tuning patient-specific insulin data, such at basal rate, carb ratio, and insulin sensitivity. A processor searches for patterns in the data profiles and if found, recommended changes to patient-specific insulin data are provided to permit more accurate control over a patient's glucose levels.
Absstract of: US12059268B1
To better understand the impact that meals have on the blood glucose level, some individuals with diabetes have begun recording meals consumed over time. However, the relationship between meals consumed by an individual and the glycemic health state of the individual has been difficult to understand. Introduced here are computer programs and associated computer-implemented techniques for utilizing information regarding the meals consumed by an individual to manage the blood glucose level of the individual in a personalized manner. By consistently and properly attributing physiological responses represented as excursions in blood glucose measurements to meals, the relationship between these meals and the glycemic health state can be better understood. For example, by examining this relationship, a diabetes management platform may be able to identify appropriate recommendations for monitoring, managing, and/or improving the glycemic health state of an individual.
Absstract of: USRE50075E
Apparatus and methods calculate and deliver doses of insulin and optionally glucagon into a subject. Online operation controls delivery of correction doses of insulin automatically in response to regular glucose measurements from a sensor, and offline operation calculates and delivers correction doses based on isolated glucose measurements and information gathered autonomously during preceding online operation. In another aspect, offline operation includes automatically calculating and administering meal doses based on information gathered autonomously during preceding periods of online operation. Both methods include generating relevant control parameters tailored to the individual and continually converged upon and potentially modulated during online operation. The control parameters are employed in real time during periods of offline operation to regulate glucose level without the need for user-provided control parameters such as correction factors and insulin-to-carbohydrate ratios.
Absstract of: LU506395B1
The invention relates to a comprehensive equipment for improving glucose and lipid metabolism levels and its application . It includes an exercise device , a wearable monitoring device , and a main control mechanism. The input end of the main control mechanism communicates with the wireless data of the wearable monitoring device. connection, the collected blood sugar and blood lipid parameters are sent to the main control mechanism at intervals, and the heart rhythm parameters are continuously sent to the main control mechanism; the serial port of the main control mechanism is connected to the 1/0 control end of the exercise device, and according to the initial settings Control the power and other paramecters of the exercise device at regular intervals, and at the same time modify and adjust the control logic according to blood sugar, blood lipids, and heart rhythm parameters. This device has significant practical effects and has a solid theoretical basis for its application method. Its HIIT application method has better compliance than MICT . It also has better blood sugar improvement effect. It is especially suitable for patients with type 2 diabetes to conduct guided or Autonomous rehabilitation.
Absstract of: US2024260867A1
A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.
Absstract of: US2024260866A1
A method, apparatus, and a kit are capable of improving accuracy of CGS devices using dynamic outputs of continuous glucose sensors.
Nº publicación: US2024260861A1 08/08/2024
Applicant:
SENSEONICS INCORPORATED [US]
Senseonics, Incorporated
Absstract of: US2024260861A1
A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and a multiple metal protective system including multiple metals incorporated in and/or in close proximity to a surface of the analyte indicator that reduce deterioration of the analyte indicator.
BOPI
Electronic site
